Skip to main content

Lion CEO Friederich Von Bohlen To Step Down

NEW YORK, Dec. 15 (GenomeWeb News) - Friedrich von Bohlen, the CEO of Lion Bioscience, has announced his resignation, which will be effective December 31st, the Heidelberg, Germany company said today.

 

"Dr. von Bohlen and the supervisory board are convinced that Lion is now entering into a new phase of development that requires even stronger IT competence," the company said in a statement issued today. "With this milestone, Dr. von Bohlen proactively allows for new opportunities at Lion."

 

Von Bohlen, a dynamic and sometimes outspoken personality, founded the company and led it through its IPO in 2000, as well as the signing of major deals with Bayer, Celera, and IBM; the acquisition of NetGenics, and several rounds of restructuring and layoffs this year and last to refocus the company on its IT strengths.

 

Martin Hollenhorst, Chief Financial Officer, and Daniel Keesman, Chief Business Officer, will lead the company beginning Jan. 1.

 

The supervisory board has proposed that von Bohlen be elected as an additional member of the board at the next shareholders meeting on Aug. 12th.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.